News

SABCS Roundtable with Dr. Howard Burris and Dr. William Gradishar


 

SAN ANTONIO – Perspectives on IBIS-II, dasatinib in combination with leutrozole, dual pathway blockade, CDK inhibitors, and more practice-changing trial results from the San Antonio Breast Cancer Symposium are discussed by Dr. Howard A. Burris, III, Chief Medical Officer and Director of Drug Development at the Sarah Cannon Research Institute, Nashville, Tenn.; and Dr. William A. Gradishar, Betsy Bramsen Professor of Breast Oncology at the Northwestern University Feinberg School of Medicine, Director of the Maggie Daley Center For Women's Cancer Care, and a member of the Robert H. Lurie Comprehensive Cancer Center, Chicago.

The video associated with this article is no longer available on this site. Please view all of our videos on the MDedge YouTube channel.

Recommended Reading

VIDEO: What's ahead for chronic myelogenous leukemia?
MDedge Internal Medicine
ASCO slams federal cuts in its annual report
MDedge Internal Medicine
Pathologic complete response to HER2 therapy portends better outcomes
MDedge Internal Medicine
Radiotherapy can be omitted for many older breast cancer patients
MDedge Internal Medicine
VIDEO: Tumor-infiltrating lymphocytes may predict trastuzumab success
MDedge Internal Medicine
Dasatinib gives letrozole a boost in HR-positive advanced breast cancer
MDedge Internal Medicine
IBIS-II: Anastrozole highly effective in preventing breast cancer
MDedge Internal Medicine
No gain seen from adjuvant bevacizumab in HER2-positive disease
MDedge Internal Medicine
Surgery adds little after successful chemo in metastatic breast cancer
MDedge Internal Medicine
Esophageal ultrasound unreliable for tumor staging
MDedge Internal Medicine